Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Dec 6, 2019 (7 years ago)

Levetiracetam Oral Solution 100mg/mL

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Microbial Contamination of Non-sterile Products: Out-of-specification results obtained for Total Aerobic Microbial Count.

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Levetiracetam Oral Solution 100mg/mL, 473 mL (16 fl. oz.) Bottles, Rx Only, Distributed by: Lannett Company, Inc. Philadelphia, PA 19136, NDC 54838-0548-80

Affected NDC 54838-0548-80

Compare with the code on your package — it is the most precise check available.

Drug: Levetiracetam

Recalling firm
Lannett Company, Inc.
NDC code
54838-0548-80
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0630-2020 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levetiracetam recalls

See all
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025
Class III · Low risk

Levetiracetam Tablets USP

Labeling; Wrong Barcode; error in the machine-readable barcode which could result in some units being read as Naproxen Tablets 500 mg. Product is labeled correctly as Levetiracetam

Terminated Labeling / mix-up McKesson Corporation dba McKesson Drug Company NDC 63739-795-10 D-0630-2021
Class II · Moderate risk

Levetiracetam Oral Solution

Defective container: Customer complaints for oral solution leaking from bottles.

Terminated Packaging defect Akorn, Inc. NDC 50383-241-16 D-0221-2021
Class II · Moderate risk

Levetiracetam Tablets

Presence of foreign tablet/capsule: A 1000 mg Levetiracetam Tablet was found in 500 gram bottle of Levetiracetam Tablets.

Terminated Particulate / foreign matter Eywa Pharma INC NDC 71930-063-52 D-0109-2021

Other recalls by Lannett Company, Inc.

All 2019 recalls
Class II · Moderate risk

Dextroamphetamine Saccharate

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Ongoing Labeling / mix-up Lannett Company Inc. D-0660-2026
Class II · Moderate risk

Niacin Extended-release Tablets

Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.

Ongoing Dissolution failure Lannett Company Inc. NDC 62175-322-46 D-0584-2026
Class III · Low risk

Primidone Tablets USP

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Lannett Company Inc. NDC 0527-1231-01 D-0533-2026